Creso Pharma Limited (ASX:CPH) has exceeded the significant milestone of selling 2.5 million lozenges of its flagship cannaQIX line globally, which represents over 100,000 packs sold since its launch in April 2018.
The company’s Co-Founder and CEO, Dr Miri Halperin Wernli, said revenue from the sale of cannaQIX lozenges in 2019 exceeded A$1 million.
The cannaQIX hemp oil derived food supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand.
“We are proud that cannaQIX has reached this milestone. The cannaQIX line is Creso Pharma’s hemp oil/vitamins and minerals based food supplement, oral cosmetic and medical cannabis, which has been developed with a unique proprietary buccal delivery system.
The products help manage stress and pain, and support better sleep. We are looking forward to upcoming launches together with our new partners in additional countries and continents such as South Africa and Latin America in 2020.”
Creso Pharma developed cannaQIX 10 to help manage stress and cannaQIX 25 and 50 to help manage chronic pain.
The initial target markets for these products were Switzerland, UK, Australia, New Zealand and Brazil. The company produces the cannaQIX range of products in Switzerland and is commercialising them in collaboration with several partners in Europe, Oceania and Latin America.
The products are being distributed through pharmacies and drug stores in Europe as well as through doctors and clinics in Oceania and Latin America.
The company’s Commercial Director, Jorge Wernli, said Creso Pharma’s cannaQIX hemp oil-derived products are unique, all Swiss-made, and produced in GMP facilities complying with local regulatory requirements.
“Creso Pharma has developed an attractive product portfolio responding to customer needs and complying with regulations.
“With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialised animal and human health products,” Mr Wernli said.
